ticker stringlengths 2 5 | disease stringlengths 3 196 | stage stringclasses 15
values | date stringlengths 19 19 | catalyst stringlengths 18 760 | label int64 -1 1 |
|---|---|---|---|---|---|
LLY | Relapsed/refractory chronic lymphocytic leukemia | Approved | 2023-01-27 00:00:00 | FDA Approved on January 27, 2023. | 1 |
TAK | Narcolepsy | Phase 2 | 2021-10-05 00:00:00 | Phase 2 trial stopped dosing and ended trial due to emergence of a safety signal, noted October 5, 2021. | -1 |
IFRX | ANCA-associated vasculitis (AAV) | Phase 2 | 2021-05-11 00:00:00 | Phase 2 data released May 11, 2021 - safe and well tolerated | 1 |
AZN | Bladder cancer | Phase 3 | 2020-03-06 00:00:00 | Phase 3 data did not meet primary endpoint. | 1 |
IONS | Chronic hepatitis B virus (CHB) | Phase 2b | 2022-06-27 00:00:00 | Phase 2b data readout reported that up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg <100 IU/mL at the end of treatment, noted June 27, 2022. | 1 |
LLY | Medullary thyroid cancer (MTC) | Phase 3 | 2023-10-21 00:00:00 | Phase 3 data presented at ESMO reported that selpercatinib demonstrated superior PFS vs control in the ITT-pembro (HR: 0.465, 95% CI: 0.309, 0.699; p-value: 0.0002) and ITT populations (HR: 0.482, 95% CI: 0.331, 0.700; p-value: 0.0001), noted October 21, 2023. | 1 |
AMGN | Chronic spontaneous urticaria | Phase 2b | 2023-10-31 00:00:00 | Phase 2b trial did not meet its primary endpoint, noted October 31, 2023. | 1 |
AGIO | Thalassemia | Phase 2 | 2022-12-12 00:00:00 | Phase 2 data reported durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis were observed for up to 72 weeks of treatment in both α- and β-thalassemia patients, noted December 12, 2022. | 1 |
NVS | Non-small cell lung cancer (NSCLC), adjuvant | Phase 3 | 2022-08-15 00:00:00 | Phase 3 trial did not meet the primary endpoint, noted August 15, 2022. | 1 |
GLMD | HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD) | Phase 2 | 2018-02-14 00:00:00 | Phase 2 top-line data released February 14, 2018 did not meet primary endpoint. | 1 |
JNJ | Multiple myeloma | Approved | 2023-08-10 00:00:00 | Approved August 10, 2023. | 1 |
NVS | Acute myeloid leukemia (AML) | Approved | 2017-04-28 00:00:00 | Priority review granted November 14, 2016. Approval announced April 28, 2017. | 1 |
BGNE | Nasopharyngeal cancer (RM-NPC) | Phase 3 | 2022-04-19 00:00:00 | Additional Phase 3 data reported that progression-free survival was 15.5 months, noted April 19, 2022. | 0 |
APLT | Diabetic cardiomyopathy (DbCM) | Phase 3 | 2023-06-22 00:00:00 | Phase 3 baseline data to be presented at ADA showed a strong statistical correlation between elevations in the cardiac stress biomarker, NT-proBNP, reduced cardiac functional capacity and physical activity, underscoring the importance of early diagnosis via NT-proBNP and impact of DbCM on physical function and quality ... | 1 |
NBIX | Huntington's disease | Approved | 2023-08-18 00:00:00 | Approved August 18, 2023. | 1 |
TVTX | Classical homocystinuria (HCU) | Phase 1/2 | 2023-05-31 00:00:00 | Additional Phase 2 data reported that treatment was well tolerated, with dose-dependent reductions in tHcy as previously observed in the highest BIW dosed cohorts, noted July 6, 2023. | 1 |
INVA | cIAI (complicated intra-abdominal infections) | Approved | 2018-08-27 00:00:00 | FDA approval announced August 27, 2018. | 1 |
INCY | Alopecia Areata | Approved | 2022-06-14 00:00:00 | Approved June 14, 2022. | 1 |
EVO | High adenosine signature cancers | Phase 1 | 2023-04-19 00:00:00 | Phase 1 objectives were achieved in a healthy volunteer study, confirming pharmacokinetics, pharmacodynamics, safety, and tolerability, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study in combination with a PD-1 inhibitor in patients with RCC and NSCLC, noted April 19, 2023 | 1 |
APM | Neuroblastoma | Phase 1/2 | 2023-06-22 00:00:00 | Phase 1b/2a trial has been repurposed for small molecule drug , noted June 22, 2023. | 0 |
AGIO | Pyruvate Kinase Deficiency | Phase 3 | 2022-06-10 00:00:00 | Phase 3 new patient outcome reported that 28/78 (35.9%) of all patients achieved a normal hemoglobin level at least once during treatment, noted June 10, 2022. | 1 |
SELB | Chronic Refractory Gout | Phase 3 | 2023-03-21 00:00:00 | Phase 3 top-line data reported that both trials met their primary endpoints, noted March 21, 2023. | 0 |
GKOS | Progressive keratoconus | Phase 3 | 2021-02-25 00:00:00 | Phase 3 trial met primary endpoint - February 25, 2021. | 0 |
LPTX | Biliary tract cancer (BTC) | Phase 1/2 | 2018-12-14 00:00:00 | Phase 1/2 data released December 14, 2018 noted 21.3% PR rate. | 0 |
BMY | Multiple Myeloma | Phase 3 | 2020-03-09 00:00:00 | Phase 3 trial did not meet progression-free survival primary endpoint. | 1 |
ENTA | Hepatitis C virus (HCV) | Approved | 2017-08-03 00:00:00 | Approval announced August 3, 2017. | 1 |
NRXP | COVID-19 | Phase 2/3 | 2021-10-14 00:00:00 | Data from ineligible subjects for the Phase 2b/3 trial recorded a 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment, noted October 14, 2021. | 1 |
PFE | Obsessive compulsive disorder (OCD) | Phase 2/3 | 2020-06-24 00:00:00 | Phase 2/3 top-line data did not meet primary endpoint. | 1 |
JAZZ | Small cell lung cancer (SCLC) | Phase 3 | 2020-12-03 00:00:00 | Phase 3 trial did not meet overall survival endpoint - December 3, 2020. | 1 |
FBIO | Non-small cell lung cancer (NSCLC) | Phase 1/2 | 2018-09-25 00:00:00 | Phase 1/2 preliminary data released September 24, 2018. | 0 |
CDXS | Phenylketonuria (PKU) | Phase 1 | 2018-11-08 00:00:00 | Phase 1 trial met endpoints - November 8, 2018. | 0 |
AZN | COVID-19 vaccine (variant) | Phase 2/3 | 2022-02-10 00:00:00 | Phase 2/3 trial met primary endpoint, noted February 10, 2022. | 0 |
SCPH | Chronic heart failure | Phase 2 | 2022-07-12 00:00:00 | Phase 2 trial data reported a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to "treatment as usual" at day 30, noted July 12, 2022. | 1 |
SNPX | Multiple sclerosis (MS) | Phase 1 | 2023-07-19 00:00:00 | IND submitted to FDA, noted July 19, 2023 | 0 |
EXEL | Solid Tumors | Phase 1/2 | 2022-01-18 00:00:00 | Phase 1/2 cohort results showed that of the 36 patients enrolled in cohort 2 of the CAMILLA trial, 29 were evaluable for the efficacy analysis. The primary outcome of investigator-assessed ORR per modified RECIST version 1.1 was 27.6%. The confirmed PR rate was 20.7%, and the DCR was 86.2%. Median PFS was 3.8 months, w... | 1 |
OPTN | Nasal polyps | Approved | 2017-09-17 00:00:00 | Approval announced September 18, 2017 (prior to IPO). | 1 |
IPSEY | Fibrodysplasia ossificans progressiva (FOP) | Approved | 2023-08-16 00:00:00 | FDA Approved on August 16, 2023. | 1 |
CHRS | Wet age-related macular degeneration (wAMD), among others | Approved | 2022-08-02 00:00:00 | Biosimilar approved August 2, 2022. | 1 |
ADVM | Wet age-related macular degeneration (Wet-AMD) | Phase 2 | 2022-11-04 00:00:00 | Phase 2 end-of-study results reported that all 2E11 participants were inflammation free at the end of the study, noted November 4, 2022. | 0 |
JNJ | Relapsing multiple sclerosis | Phase 3 | 2019-07-26 00:00:00 | Phase 3 trial met primary endpoint. | 0 |
NKTR | Renal Cell Carcinoma (RCC) | Phase 3 | 2022-04-14 00:00:00 | Phase 3 data reported that trial did not met its endpoints of objective response rate (ORR) and overall survival (OS), noted April 14, 2022. | 0 |
ONCT | Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) | Phase 1/2 | 2022-12-12 00:00:00 | Phase 1/2 data reported that the ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of 66% and CR rate of 20% for ibrutinib monotherapy, noted December 12, 2022, | 1 |
RGNX | Homozygous familial hypercholesterolemia (HoFH) | Phase 1/2 | 2020-08-06 00:00:00 | Development to be discontinued - noted August 6, 2020. | -1 |
SGEN | Frontline Hodgkin lymphoma | Approved | 2018-04-04 00:00:00 | sBLA approval announced March 20, 2018. | 1 |
PFE | Glioblastoma (GBM) | Phase 2/3 | 2023-10-31 00:00:00 | Phase 2/3 data reported that it did not perform better than the current standards of care in glioblastoma, noted October 31, 2023. | 0 |
NVS | Non-small cell lung cancer (NSCLC) with BRAF V600E mutation | Approved | 2017-06-22 00:00:00 | FDA Approval announced June 22, 2017. | 1 |
MDGL | Heterozygous familial hypercholesterolemia (HeFH) | Phase 2a | 2018-04-03 00:00:00 | Phase 2 top-line data released February 8, 2018 - primary endpoint met. | 0 |
BPMC | Non-advanced systemic mastocytosis (SM) | Approved | 2023-05-22 00:00:00 | FDA approval on May 22, 2023. | 1 |
BGNE | Waldenström’s macroglobulinemia | Approved | 2021-09-01 00:00:00 | FDA Approval announced September 1, 2021. | 1 |
MOR | Ulcerative colitis | Phase 2b | 2022-10-24 00:00:00 | Phase 2b study data reported that treatment led to a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24, noted October 24, 2022. | 1 |
TAK | Complex Crohn's Perianal Fistulas (CPF) | Phase 3 | 2023-10-18 00:00:00 | Phase 3 trial did not meet its primary endpoint, noted October 18, 2023. | 1 |
AZN | Type 2 diabetes | Approved | 2019-05-03 00:00:00 | FDA approval announced May 3, 2019. | 1 |
ALT | Non-alcoholic steatohepatitis (NASH) - Healthy, Overweight and Obese Volunteers | Phase 2 | 2023-03-21 00:00:00 | Phase 2 interim 24-week data data showed that approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at the 1.8 mg and 2.4 mg doses at Week 24. Treatment discontinuation rates were 28.2% in subjects receiving placebo and 24.0% in subjects receiv... | 1 |
EYEN | Mydriasis (office-based pupil dilation) | Approved | 2023-11-02 00:00:00 | FDA supplemental approval on November 1, 2023. | 1 |
GMAB | Relapsing multiple sclerosis | Approved | 2020-08-20 00:00:00 | FDA approval announced August 20, 2020. | 1 |
VCNX | Resectable Stage III melanoma | Phase 1 | 2022-11-10 00:00:00 | Phase 1 data presented at SITC showed that 100% of patients who received the triple combination were recurrence free at 24 months. This contrasted with recurrence free survival of less than 40% in patients who received the dual combination of pepinemab and nivolumab or pepinemab and ipilimumab, noted November 10, 2022. | 1 |
CGEN | Ovarian Cancer | Phase 1 | 2022-11-07 00:00:00 | Preliminary Phase 1 data reported a 12% ORR in 3L+ MSS-CRC patients with liver metastases, noted November 7, 2022. | 0 |
LLY | Type 2 Diabetes | Approved | 2020-01-27 00:00:00 | FDA Approval announced January 27, 2020. | 1 |
AZN | Third-line ovarian cancer | Phase 3 | 2018-12-20 00:00:00 | Phase 3 data released December 20, 2018 met primary and secondary endpoints. | 0 |
VIR | COVID-19 antibody | Approved | 2022-02-11 00:00:00 | EUA granted by FDA February 11, 2022. | 0 |
CNCE | Alopecia areata | Phase 3 | 2022-11-21 00:00:00 | Additional data reported that for patients with an absolute Severity of Alopecia Tool (SALT) score less than 95 at baseline, 43% and 57% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24, noted November 21, 2022. | 1 |
LXRX | Heart failure | Approved | 2023-05-26 00:00:00 | Approved May 26, 2023. | 1 |
VRTX | Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations | Approved | 2015-03-17 00:00:00 | Approved March 17, 2015. | 1 |
TAK | Eosinophilic esophagitis | CRL | 2021-12-21 00:00:00 | CRL December 21, 2021. | 0 |
GSK | Multiple Myeloma | Phase 3 | 2022-11-07 00:00:00 | Phase 3 trial did not meet its primary endpoint, noted November 7, 2022. | 1 |
CYTO | COVID-19 | Phase 1 | 2023-01-24 00:00:00 | Phase 1 topline data reported that trial did not meet primary endpoint, noted January 24, 2023. | 1 |
ALGS | Hepatitis B | Phase 1 | 2023-06-21 00:00:00 | Phase 1 data presented at EASL resulted in dose-dependent reductions in HBsAg levels through 90 days. Importantly, the safety and PK profile of these dose levels also support further evaluation of higher dose levels, noted June 21, 2023. | 1 |
BLUE | Sickle Cell Disease | Phase 3 | 2021-02-16 00:00:00 | Phase 3 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021. | 0 |
PFE | Acute myeloid leukemia (AML) | Approved | 2018-11-21 00:00:00 | FDA approval announced November 21, 2018. | 1 |
AZN | Anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) | Approved | 2022-04-28 00:00:00 | Approved April 28, 2022. | 1 |
JAZZ | Multiple sclerosis (MS)-related spasticity | Phase 3 | 2022-06-28 00:00:00 | Phase 3 trial did not meet the primary endpoint, noted June 28, 2022. | 1 |
HOTH | EGFRI-induced skin toxicity | Phase 2a | 2023-06-14 00:00:00 | Received written approval from the Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001, noted June 14, 2024. | 1 |
ABBV | Crohn’s Disease | Approved | 2022-06-17 00:00:00 | Approved June 17, 2022. | 1 |
FOLD | Pompe Disease | Approved | 2023-09-28 00:00:00 | FDA Approved on September 28, 2023. | 1 |
NUVL | ALK non-small cell lung cancer (NSCLC) | Phase 1 | 2023-10-13 00:00:00 | Phase 1 trial showed preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and lorlatinib, have brain metastases, or have single or compound ALK resistance mutations, noted October 13, 2023... | 1 |
BMY | Follicular lymphoma | Phase 2 | 2023-06-17 00:00:00 | Phase 2 data presented at ICML showed that 97% of patients with R/R FL treated with Breyanzi achieved a response, with 94% achieving a complete response, and 81.9% of responders in ongoing response at 12 months, noted June 17, 2023. | 1 |
CRDF | Small cell lung cancer (SCLC) | Phase 2 | 2023-09-26 00:00:00 | Phase 2 safety data from the first six patients by the institutional review board confirmed the trial can continue to enroll as planned, noted September 26, 2023. | 0 |
IKNA | Solid tumors and urothelial carcinoma, bladder cancer | Phase 1 | 2022-11-10 00:00:00 | Phase 1 data presented at SITC showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma. Monotherapy activity observed; confirmed partial response with DoR of 14.9 months and ongoing, noted November 10, 2022. | 1 |
GILD | Hepatitis C virus (HCV) | Approved | 2017-07-18 00:00:00 | Approval announced July 18, 2017. | 1 |
NGM | Pancreatic Cancer | Phase 1b | 2021-09-16 00:00:00 | Phase 1b data had all 6 patients demonstrated disease control, 3 patients had partial responses (PR), and 3 stable disease (SD). 2 patients discontinued early due to gemcitabine/Nab-paclitaxel toxicity and/or progression of the underlying disease. Phase 1a monotherapy cohort reported 3 patients (30%) in the 30 mg dosin... | 1 |
GLPG | Cutaneous lupus erythematosus (CLE) | Phase 2 | 2019-10-24 00:00:00 | Phase 2 trial did not meet primary endpoint. | 1 |
BGNE | Stage II-IIIA non-small cell lung cancer (NSCLC) | Phase 3 | 2023-10-23 00:00:00 | Phase 3 data presented at ESMO reported that MPR & pCR rates were significantly improved with TIS + CT vs CT, noted October 23, 2023. | 1 |
LGVN | Hypoplastic Left Heart Syndrome | Phase 1b | 2023-05-09 00:00:00 | Phase 1b long term data reported that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B, noted May 9, 2023. | 0 |
RHHBY | Pemphigus vulgaris | Phase 3 | 2019-06-13 00:00:00 | Phase 3 trial met primary and secondary endpoints - June 13, 2019. | 0 |
JNJ | Influenza | Phase 2a | 2023-06-22 00:00:00 | FDA has granted Fast Track designation (FTD), noted June 22, 2023. | 0 |
OMER | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 1b | 2023-11-02 00:00:00 | Phase 1b data from ASH abstract reported that mean Hgb increased from baseline by 3.1 g/dL at 4 weeks, and by 9.5 g/dL at the latest timepoint of 24 weeks, noted November 2, 2023. | 0 |
LLY | Diabetes | Approved | 2020-06-15 00:00:00 | FDA Approval announced June 15, 2020. | 1 |
ATOS | Breast cancer | Phase 2 | 2021-06-09 00:00:00 | Phase 2 final data presented June 9, 2021. Primary endpoint met. | 1 |
JANX | Metastatic castration-resistant prostate cancer (mCPRC) | Phase 1 | 2023-07-17 00:00:00 | Phase 1 interim clinical data showed tumor-activated T cell engagement in patients with prostate cancer representing the first-in-human data for the TRACTr platform and providing confidence for continuing clinical development of JANX007 and advancing future programs from the platform, noted July 17, 2023. | 1 |
JNJ | Waldenström’s Macroglobulinemia | Approved | 2018-08-27 00:00:00 | FDA approval announced August 27, 2018. | 1 |
BIIB | Postpartum Depression | Approved | 2023-08-04 00:00:00 | Approved August 4, 2023. | 1 |
MRK | Metastatic Melanoma | Phase 2b | 2023-10-31 00:00:00 | Phase 2b data presented at SITC reported that a pronounced and ongoing tumor reduction was observed in a patient with progressive disease, noted October 31, 2023. | 1 |
ZVRA | Niemann-Pick disease Type C (NPC) | CRL | 2021-06-18 00:00:00 | CRL issued June 18, 2021. | 0 |
ONCY | HR+ / HER2- breast cancer | Phase 2 | 2023-06-05 00:00:00 | Phase 2 data readout at ASCO reported that nine pts (33%) discontinued pelareorep and 6 (35%) discontinued avelumab due to toxicity, noted June 5, 2023. | -1 |
OBSV | In Vitro Fertilization (IVF) | Phase 3 | 2018-02-26 00:00:00 | Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3. | 1 |
BIVI | Alzheimer's disease | Phase 2 | 2022-12-05 00:00:00 | Additional Phase 2 data reported that 18 of 22 patients with abnormal baseline scans showed improvement in one or more brain regions as seen from advanced functional MRI studies, noted December 5, 2022. | 1 |
ADVM | Diabetic macular edema (DME) | Phase 2 | 2021-10-09 00:00:00 | Phase 2 data from trial (June 22, 2021, cutoff date, n=34) at ASRS demonstrated that dose and disease state appear to have an impact in determining the therapeutic window which balances efficacy and safety. Dose-dependent inflammation observed may be in part related to the study population which included patients with ... | 1 |
TSVT | Multiple Myeloma | Phase 3 | 2023-02-10 00:00:00 | Full Phase 3 data presented at EBMT-EHA 5th European CAR T-cell meeting demonstrated more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma, risk of disease progression or death was reduced by 51% versus standard regimens, noted... | 1 |
RETA | CKD Patients at Risk of Rapid Progression | Phase 2 | 2023-05-10 00:00:00 | Program discontinued, noted May 10, 2023. | -1 |
CUE | HPV16+ head and neck cancer | Phase 1 | 2023-11-03 00:00:00 | Phase 1 data shared at SITC showed an overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) HNSCC patients treated with CUE-101 and pembrolizumab. ORR of 56% in patients with low expression of PD-L1 in the tumor, noted November 3, 2023. | 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.